Deliver Your News to the World

Nine "Cash Plus Catalyst" FDA Decision & Clinical Trial Trades


LOS ANGELES - 05/11/09 - In a new special report, the news portal covering the biomedical news and financial sector- is profiling nine ’Cash Plus Catalyst’ trades which include companies that are currently trading for around 2X net cash/equivalents or less (the ratio of market cap to cash/equivalents less debt) with pending FDA decisions, clinical trial results, or pending FDA submissions.

The following companies met the screening requirements, and all have pivotal FDA deadline dates and/or events, so they are all profiled in the report for investors:

BioForm Medical (NASDAQ:BFRM): Market Cap = $59.8M, Net Cash = $41.4M.
Spectrum Pharma (NASDAQ:SPPI): Market Cap = $119.1M, Net Cash = $70.5M.
Nanosphere (NASDAQ:NSPH): Market Cap = $81.4M, Net Cash = $58.2M.
Vivus (NASDAQ:VVUS): Market Cap = $310M, Net Cash = $176.6M.
Amicus Therapeutics (NASDAQ:FOLD): Market Cap = $174M, Net Cash = $108M.
Pain Therapeutics (NASDAQ:PTIE): Market Cap = $179M, Net Cash = $185.6M.
Biodel (NASDAQ:BIOD): Market Cap = $93M, Net Cash = $72.1M.
Avanir Pharma (NASDAQ:AVNR): Market Cap = $62.6M, Net Cash = $30.5M.
Orexigen Therapeutics (NASDAQ:OREX): Market Cap = $96.7M, Net Cash = $64.7M.

A full special report detailing all of the FDA events and Clinical Trials updates appears today at


About BioMedReports.Com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.

For more biomedical sector and investment news, go to

Disclosure: No positions.

Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. BiomedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.


 FDA Approval
 Clinical Trials
 Drug Approval

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.